---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-408224"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2026-09-30T10:09:56+00:00"
generated_at: "2026-10-12T13:55:46.490044+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sagimet: denifanstat hits 56.7% IGA success at 52 weeks in Ascletis Phase 3 OLE; US AURORA screening starts October

## Summary
- 52-week Phase 3 OLE (ASC40-304) in China: 56.7% treatment success across 240 patients (57.8% denifanstat/denifanstat vs 55.6% placebo/denifanstat).
- Mean reductions vs ASC40-303 baseline: total lesion count -71.8%, inflammatory lesions -76.9%, non-inflammatory lesions -66.9%.
- Denifanstat 50 mg was generally well-tolerated up to 52 weeks: no permanent discontinuations or drug-related serious AEs; dry skin 7.1%, dry eye 5.9%.
- Sagimet's US AURORA Phase 3 screening begins October 2026: ~800 patients (450 aged 12-17), randomized 2:1 to denifanstat 50 mg or placebo over 12 weeks.
- Sagimet terminated the ATM prospectus supplement under its Aug 14, 2025 Sales Agreement with Leerink Partners; no further share sales unless a new prospectus is filed.

## SEC filing metadata
- accession: 0001193125-26-408224
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2026-09-30T10:09:56+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000119312526408224/0001193125-26-408224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000119312526408224/d96035d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-408224
- JSON: https://secwatch.observer/filing/0001193125-26-408224.json
- Plain text: https://secwatch.observer/filing/0001193125-26-408224.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.